| __timestamp | Mesoblast Limited | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 54170000 | 504755000 |
| Thursday, January 1, 2015 | 65378000 | 838526000 |
| Friday, January 1, 2016 | 52263000 | 1177697000 |
| Sunday, January 1, 2017 | 35072000 | 1320433000 |
| Monday, January 1, 2018 | 27415000 | 1556200000 |
| Tuesday, January 1, 2019 | 36983000 | 1834800000 |
| Wednesday, January 1, 2020 | 50918000 | 1346000000 |
| Friday, January 1, 2021 | 63586000 | 1824900000 |
| Saturday, January 1, 2022 | 57967000 | 2115900000 |
| Sunday, January 1, 2023 | 53107000 | 2631300000 |
| Monday, January 1, 2024 | 23626000 | 2954400000 |
Data in motion
In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Regeneron Pharmaceuticals, Inc. and Mesoblast Limited from 2014 to 2023. Regeneron, a leader in the biotech industry, has seen its SG&A expenses grow by over 400% during this period, peaking at approximately $2.6 billion in 2023. In contrast, Mesoblast's expenses have fluctuated, with a notable decrease of around 55% from 2015 to 2024. This divergence highlights Regeneron's aggressive expansion and investment in administrative capabilities, while Mesoblast appears to be optimizing its operational costs. The data reveals a strategic shift in the biotech landscape, where financial management plays a pivotal role in sustaining growth and innovation. Missing data for 2024 suggests ongoing developments that could further influence these trends.
Selling, General, and Administrative Costs: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Sanofi vs Regeneron Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Genmab A/S
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Incyte Corporation vs Mesoblast Limited Trends and Insights
Pharming Group N.V. or Mesoblast Limited: Who Manages SG&A Costs Better?
ACADIA Pharmaceuticals Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Mesoblast Limited vs Celldex Therapeutics, Inc. Trends and Insights